Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 79, Issue 2, Pages 182-194Publisher
WILEY
DOI: 10.1111/bcp.12403
Keywords
adherence; antiretroviral; drug interactions; human immunodeficiency virus; pharmacogenomics; therapeutic drug monitoring
Categories
Funding
- ViiV Healthcare
- Janssen
- Merck Pty Ltd
- Gilead
- AbbVie
- Bristol Myers Squibb
Ask authors/readers for more resources
The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available